Meta-analysis: Efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 12, 2011, Pages 1100-1110

  Lin, Ziwei ^a   Bai, Yu ^b   Zheng, Ping ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

combination therapy; Crohn's disease; immunosuppressives; infliximab

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISOLONE; PREDNISONE; STEROID;

COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENETIC HETEROGENEITY; HOSPITALIZATION; HUMAN; INFECTION; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; META ANALYSIS; MONOTHERAPY; NEOPLASM; PRIORITY JOURNAL; REVIEW; SEPSIS; SIDE EFFECT; TREATMENT FAILURE; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80955130782     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834b9544     Document Type: Review

References (20)

1. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104:465-483.
2. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-1395.
3. Lemann M, Mary J, Duclos B, Veyrac M, Dupas J, Delchier JC, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-1061.
4. Schrö der O, Blumenstein I, Stein J. Combining infliximab with methotrexate for induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroen Hepat 2006; 18:11-16. (Pubitemid 43004875)
5. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30:210-226.
6. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359:1541-1549. (Pubitemid 34621118)
7. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876-885. (Pubitemid 38252535)
8. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12. (Pubitemid 26120810)
9. Baert F, Norman M, Vermeire S, Assche GV, Haens GD, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601-608. (Pubitemid 36204954)
10. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb G. Chimeric anti-TNF-a monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7:251-259.
11. Roblin X, Serre-Debeauvais F, Phelip JM, Bessard G, Bonaz B. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18:917-925. (Pubitemid 37346676)
12. Vermeire S, Noman M, Assche GV, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56:1226-1231. (Pubitemid 47300423)
13. Schröder O, Blumenstein I, Schulte-Bockholt A, Stein J. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther 2004; 19:295-301. (Pubitemid 38253504)
14. Topstad DR, Panaccione R, Heine JA, Johnson DRE, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003; 46: 577-583. (Pubitemid 36576412)
15. Ochsenkuhn T, Goke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol 2002; 97:2022-2025.
16. Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 2003; 98:608-612. (Pubitemid 36348533)
17. Regueiro M, Siemanowski B, Kip KE, Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007; 13:1093-1099. (Pubitemid 47402592)
18. Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fitall. Clin Gastroenterol Hepatol 2010; 8:655-659.
19. Assche GV, Magdel-Beuzelin C, D'haen G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134:1861-1868. (Pubitemid 351790744)
20. Oussalah A, Chevaux J, Fay R, Sandborn WJ, Bigard M, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010; 105:1142-1149.